Tonix Pharmaceuticals Holding TNXP Stock
Tonix Pharmaceuticals Holding Price Chart
Tonix Pharmaceuticals Holding TNXP Financial and Trading Overview
Tonix Pharmaceuticals Holding stock price | 17.8 USD |
Previous Close | 15.21 USD |
Open | 14.35 USD |
Bid | 14.61 USD x 100 |
Ask | 15 USD x 100 |
Day's Range | 13.71 - 18 USD |
52 Week Range | 11.8 - 1248 USD |
Volume | 2.04M USD |
Avg. Volume | 1.23M USD |
Market Cap | 83.74M USD |
Beta (5Y Monthly) | 2.077 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -176.6 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 583.33 USD |
TNXP Valuation Measures
Enterprise Value | 8.21M USD |
Trailing P/E | N/A |
Forward P/E | -0.4846328 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.72217 |
Price/Book (mrq) | 0.26002428 |
Enterprise Value/Revenue | 0.659 |
Enterprise Value/EBITDA | -0.09 |
Trading Information
Tonix Pharmaceuticals Holding Stock Price History
Beta (5Y Monthly) | 2.077 |
52-Week Change | -98.58% |
S&P500 52-Week Change | 20.80% |
52 Week High | 1248 USD |
52 Week Low | 11.8 USD |
50-Day Moving Average | 29.91 USD |
200-Day Moving Average | 107.72 USD |
TNXP Share Statistics
Avg. Volume (3 month) | 1.23M USD |
Avg. Daily Volume (10-Days) | 1.8M USD |
Shares Outstanding | 1.87M |
Float | 22M |
Short Ratio | 0.35 |
% Held by Insiders | 0.16% |
% Held by Institutions | 0.22% |
Shares Short | 7.67M |
Short % of Float | 5.48% |
Short % of Shares Outstanding | 5.48% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:100 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2023 |
Most Recent Quarter (mrq) | June 30, 2024 |
Next Fiscal Year End | December 31, 2024 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -831.47% |
Gross Margin | 21.59% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -51.72% |
Return on Equity (ttm) | -163.24% |
Income Statement
Revenue (ttm) | 12.46M USD |
Revenue Per Share (ttm) | 6.35 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 2.69M USD |
EBITDA | -90770000 USD |
Net Income Avi to Common (ttm) | -149012000 USD |
Diluted EPS (ttm) | -8039 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 4.16M USD |
Total Cash Per Share (mrq) | 0.19 USD |
Total Debt (mrq) | 9.26M USD |
Total Debt/Equity (mrq) | 21.99 USD |
Current Ratio (mrq) | 1.147 |
Book Value Per Share (mrq) | 57.61 |
Cash Flow Statement
Operating Cash Flow (ttm) | -73219000 USD |
Levered Free Cash Flow (ttm) | -44012248 USD |
Profile of Tonix Pharmaceuticals Holding
Country | United States |
State | NJ |
City | Chatham |
Address | 26 Main Street |
ZIP | 07928 |
Phone | 862 799 8599 |
Website | https://www.tonixpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 103 |
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Q&A For Tonix Pharmaceuticals Holding Stock
What is a current TNXP stock price?
Tonix Pharmaceuticals Holding TNXP stock price today per share is 17.8 USD.
How to purchase Tonix Pharmaceuticals Holding stock?
You can buy TNXP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tonix Pharmaceuticals Holding?
The stock symbol or ticker of Tonix Pharmaceuticals Holding is TNXP.
Which industry does the Tonix Pharmaceuticals Holding company belong to?
The Tonix Pharmaceuticals Holding industry is Biotechnology.
How many shares does Tonix Pharmaceuticals Holding have in circulation?
The max supply of Tonix Pharmaceuticals Holding shares is 6.88M.
What is Tonix Pharmaceuticals Holding Price to Earnings Ratio (PE Ratio)?
Tonix Pharmaceuticals Holding PE Ratio is now.
What was Tonix Pharmaceuticals Holding earnings per share over the trailing 12 months (TTM)?
Tonix Pharmaceuticals Holding EPS is -176.6 USD over the trailing 12 months.
Which sector does the Tonix Pharmaceuticals Holding company belong to?
The Tonix Pharmaceuticals Holding sector is Healthcare.
Tonix Pharmaceuticals Holding TNXP included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
9.99B USD — | 14784.03 USD — | 16292.28 USD — | — - | 9.99B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}